Lung Transplantation — Long-Term Management
Lifelong post-transplant care including triple immunosuppression (calcineurin inhibitor + antimetabolite + corticosteroid), surveillance bronchoscopy, vigilance for chronic lung allograft dysfunction (CLAD — bronchiolitis obliterans syndrome and restrictive allograft syndrome), opportunistic infection prevention, and malignancy screening.
This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.
This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →
What is Lung Transplantation — Long-Term Management?
Lung transplantation is the only definitive therapy for end-stage lung disease that is refractory to maximal medical therapy and not amenable to other interventions. Indications include idiopathic pulmonary fibrosis and other interstitial lung diseases (40–50 percent), chronic obstructive pulmonary disease (15–25 percent), cystic fibrosis (10–15 percent), pulmonary arterial hypertension (5 percent), alpha-1 antitrypsin deficiency emphysema (5 percent), and others. Bilateral lung transplant (BLT) is preferred for most indications and yields better long-term outcomes than single lung transplant (SLT) — median survival 7 years for BLT vs 4.5 years for SLT (ISHLT 2022).
Long-term immunosuppression: typical maintenance regimen is triple therapy with calcineurin inhibitor (tacrolimus preferred over cyclosporine for better acute rejection control and CLAD prevention; trough goals 8–12 ng/mL early then 5–10 ng/mL late) + antimetabolite (mycophenolate mofetil 1–1.5 g BID — preferred over azathioprine; some use mTOR inhibitor sirolimus or everolimus instead) + corticosteroid (prednisone tapered to 5 mg daily by 1 year). Monitoring: tacrolimus levels, CBC, BMP, lipids, glucose, magnesium, infection screens.
Chronic lung allograft dysfunction (CLAD): leading cause of late death after lung transplant; defined by ISHLT 2019 criteria as persistent decline of FEV1 ≥ 20 percent from baseline; two phenotypes — (1) bronchiolitis obliterans syndrome (BOS, obstructive — 70 percent, fibrotic obliteration of small airways with air trapping); (2) restrictive allograft syndrome (RAS, restrictive — 30 percent, parenchymal fibrosis with poor prognosis, 1-year survival 30 percent vs BOS 70 percent). Risk factors: acute cellular rejection, antibody-mediated rejection, donor-specific antibodies, CMV infection, GERD with aspiration, Pseudomonas aeruginosa airway colonization, bronchiolitis obliterans organizing pneumonia (BOOP). Treatment is challenging — azithromycin (anti-inflammatory), montelukast, switching to mTOR inhibitor, photopheresis, total lymphoid irradiation, and ultimately re-transplantation.
Symptoms
Risk Factors
When to See a Doctor?
If you experience any of the following symptoms, seek medical attention promptly:
- Decline in home spirometry (PEF or FEV1) > 10 percent — urgent evaluation
- New cough, dyspnea, fever in lung transplant recipient
- Symptoms of CMV (fever, fatigue, cytopenia, GI symptoms, retinitis)
- New skin lesion (any) — dermatology referral mandatory
- Lymphadenopathy, weight loss, fever (PTLD workup)
- GERD symptoms
- New onset diabetes or worsening glycemic control
- Renal function decline
- Missed immunosuppressant doses (urgent contact with transplant center)
Treatment Methods
Which Department to Visit?
You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.
Learn About Göğüs Hastalıkları DepartmentLet us help you
You can make an appointment with our specialists or contact us for your concerns.
Related Health Topics
Other articles from the same department you may want to explore.
Asthma
Göğüs Hastalıkları
Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.
COPD (Chronic Obstructive Pulmonary Disease)
Göğüs Hastalıkları
COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.
Pneumonia
Göğüs Hastalıkları
Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.
Tuberculosis (TB)
Göğüs Hastalıkları
Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.
Pleural Effusion
Göğüs Hastalıkları
Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.
Pneumothorax
Göğüs Hastalıkları
Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.
Bronchitis (Acute and Chronic)
Göğüs Hastalıkları
Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.
Bronchiectasis
Göğüs Hastalıkları
Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.
Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.